Lenalidomide/revlimid dose
Active Purchase Order Awarded Last action
- Contract number
- 36C25226P0105
- Awardee
-
Exelan Pharmaceuticals Inc. UEI FYZXNHSQTMG8
- Awarding agency
-
Veterans Integrated Service Network 12
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,000,000
Award facts
- Opportunity
-
- 6505--Lenalidomide (Revlimid) Dose-Brand name only Pre-Solicitation · 36C25226Q0072 · Posted Oct 30, 2025
- Contract value 100% obligated
- $1,000,000.00 Current and potential, with all options
- Completion date 89% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Veterans Integrated Service Network 10 Veterans Health Administration, Department of Veterans Affairs
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Boca Raton, FL 33432, USA
Award details come from SAM.gov/FPDS.
About this award
Exelan Pharmaceuticals Inc. has been awarded a $1 million firm fixed-price purchase order by Veterans Integrated Service Network 10 (a Veterans Affairs component) for the supply of Lenalidomide/Revlimid, an oral immunomodulatory medication used to treat blood cancers. The contract, which became effective December 15, 2025, has an ultimate completion date of December 14, 2026, and will be fulfilled at the vendor's facility in Boca Raton, Florida. This award was issued without a set-aside designation, allowing Exelan to compete openly against other qualified pharmaceutical suppliers.
Exelan Pharmaceuticals, a foreign-owned pharmaceutical company specializing in manufacturing, distributing, and repackaging generic and branded pharmaceutical products for federal healthcare systems, is well-positioned to support this requirement. The company maintains extensive experience supplying the VA through multiple federal contract vehicles and holds SAM.gov registration through July 30, 2026. As a primary distributor for critical federal healthcare agencies including the Department of Veterans Affairs, Department of Defense, and the Bureau of Prisons, Exelan's existing infrastructure and established relationships with the VA support its ability to meet the pharmaceutical supply demands outlined in this procurement.
Quick answers
Who was awarded contract 36C25226P0105?
36C25226P0105 was awarded to Exelan Pharmaceuticals Inc. by Veterans Integrated Service Network 12 (Veterans Health Administration) on December 15, 2025.
How much is contract 36C25226P0105 worth?
The government has obligated $1,000,000 on 36C25226P0105.
Which agency awarded contract 36C25226P0105?
Veterans Integrated Service Network 12 (Veterans Health Administration) awarded 36C25226P0105, with funding from Veterans Integrated Service Network 10 (Veterans Health Administration).
Was contract 36C25226P0105 competed?
The extent of competition for 36C25226P0105 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award